申请人:Vertex Pharmaceuticals Incorporated
公开号:US20210052584A1
公开(公告)日:2021-02-25
The present invention features a compound of formula I:
or a pharmaceutically acceptable salt thereof, where R
1
, R
2
, R
3
, W, X, Y, Z, n, o, p, and q are defined herein, for the treatment of CFTR mediated diseases, such as cystic fibrosis. The present invention also features pharmaceutical compositions, method of treating, and kits thereof.